medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2010, Number 2

<< Back Next >>

Rev Mex Oftalmol 2010; 84 (2)

Utilidad en el uso de apraclonidina para el control de la variación de presión intraocular posterior a la aplicación de antiangiogénico intravítreo

Tinoco-Ortega R, Ortega-Santana JF, García-López A

Language: Spanish
References: 9
Page: 74-76
PDF size: 87.79 Kb.


ABSTRACT

Objectives: To determine the effects of apraclonidine as an IOP stabilizer in patients with recent application of intravitreous drugs.
Material y methods: Patients with application of intravitreous ranibizumab from May until October 2008 were included in the study. The patients were chosen randomly into the treatment group or the control group. The IOP was taken with Goldman’s tonometer before and immediately after the injection and 30 minutes, an hour and at 24 hours after the procedure.
Results: Sixty one patients (28 women y 33 men), between the ages of 45 - 75 years (mean 60 years) were studied. Eight patients were excluded due to lack of follow-up at 24 hours. The pressures of patients with and without apraclonidine showed significant differences. The pressure in the group without apraclonidine: immediately after (27 mmHg ± 6.71), 30 minutes (24.72 mmHg ± 4.99) 1 hour (22.03 mmHg ± 3.90) and 24 hours (19.09 mmHg ± 3.96); for the group with apraclonidine: immediately after (21.86 mmHg ± 3.76), 30 minutes (18.36 mmHg ± 3.66) 1 hour (16.36 mmHg ± 3.52) and 24 hours (15.13 mmHg ± 3.25). The groups were compared and showed a p ‹ 0.05 using Student’s T test.
Conclusions: The application of intravitreous ranibizumab raises IOP significantly in a 24 hour follow-up. The use of apraclonidine 10 minutes before the injection of intravitreous ranibizumab significantly reduces the magnitude of the hypertensive spikes in all the patients studied.


REFERENCES

  1. Falkenstein. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007; 27:1044-1047.

  2. Gaudreault. Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration. Invest Ophthalmol Vis Sci 2005; 46:726-733.

  3. Vasconcelos-Santos. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: Incidence and Risk Factors. Retina 2008; 28:573-580.

  4. Singh IP y cols. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004; 138:286-287.

  5. Hariprasad SM y cols. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 2006; 141:200-201.

  6. Roth y cols. Short-term complications of intravitreal injection of triamcinolone acetonide. Retina 2008; 28:66-70.

  7. Stewart y cols. A 90-Day Study of the Efficacy and Side Effects of 0.25% and 0.5% Apraclonidine vs 0.5% Timolol. Arch Ophthalmol1996; 114:938-942.

  8. Stewart y cols. The Efficacy of Apraclonidine as an Adjunct to Timolol Therapy. Arch Ophthalmol 1995; 113:287-292.

  9. Sciscio y cols. Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery. Br J Ophthalmol 2001; 85:164-168.




2020     |     www.medigraphic.com